Lung Imaging Company Sets its Sights on Tackling COPDBy Bioxydyn, PRNE
Wednesday, March 9, 2011
MANCHESTER, England, March 10, 2011 - www.bioxydyn.com
A unique, non-invasive magnetic imaging (MRI) tool is being
developed by The University of Manchester (www.manchester.ac.uk/)
spinout company Bioxydyn (www.bioxydyn.com/). It has the potential to
considerably improve the treatment of lung conditions such as chronic
obstructive pulmonary disease (COPD), asthma, cystic fibrosis and emphasema
as well as aiding cancer specialists and neuroscientists.
COPD is the world's 3rd biggest killer but Bioxydyn's
diagnostic imaging technologies have the potential to change the way in which
lung disease is diagnosed and monitored by providing non-invasive regional
assessments of lung ventilation/perfusion ratio (V/Q) and measures of changes
in pulmonary vascular function.
Bioxydyn is also developing powerful MRI based oncology tools
for quantifying tumour oxygenation and oxygen metabolism. By providing unique
non-invasive characterisation of the oxygenation status of tumours its
technologies will aid therapeutic decision making and provide additional
information for assessing the response of tumours to intervention.
Commenting on the potential for this new technology Prof.
Geoff Parker, Bioxydyn Director said: "There currently simply isn't an
inexpensive or practical 3D lung imaging technique available that can capture
the structure and function of the lung, so we feel we've got something the
market will want quickly. Lung diseases and disorders are so commonplace,
with COPD affecting 80m people and causing 3m deaths world-wide each year."
Prof. Parker continues: "We've some exciting interest from
major pharmaceutical players, so the race is on to develop our products and
engage with the market to bring this to a commercial reality as soon as
Professor Parker who is also Director of The University of Manchester's
Biomedical Imaging Institute (www.bii.manchester.ac.uk/), has been
named by the Institute of Public Policy Research as one of 50 'Northern
Lights' in recognition of his work with Bioxydyn.
Bioxydyn has received commercialisation support and advice from UMIP
(www.umip.com/) The University of Manchester's Intellectual Property
commercialisation company as well as funding from The UMIP Premier Fund
(www.theupf.com/) which makes late-seed stage investments.
In 2010 Bioxydyn was named as Startup of the Year at the
Northwest Biomedical Awards.
For more information on Bioxydyn and the MRI tool then please
check out www.bioxydyn.com
Press contact: Clare Coyne, Roland Dransfield PR, +44(0)161-236-1122
Tags: Bioxydyn, England, Manchester, March 10, United Kingdom